- Poster presentation
- Open access
- Published:
Pharmacological treatment of hypoactive delirium in critically ill patients: a systematic review
Critical Care volume 17, Article number: P36 (2013)
Introduction
Delirium is generally managed by treating its underlying causes. However, symptomatic treatment may also be indicated. Although hypoactive delirium in critically ill patients is the most prevalent subtype of delirium, the effects of treatment with drugs specifically for this group are not well defined. The aim of this systematic review is to evaluate the role of pharmacological treatment in critically ill patients with hypoactive delirium.
Methods
A systematic review was conducted, based on the PRISMA criteria, to identify articles on the pharmacological approach to hypoactive delirium in critically ill patients. First, a MEDLINE and SciELO database search was performed for articles published in the English language, involving patients in ICUs in which pharmacological therapy was used to treat delirium. Second, these studies were reevaluated to identify subtypes of delirium and the impact of the treatment.
Results
The number of studies included in the qualitative synthesis was 18. One-half of them were clinical trials and the others were either letters or comments. However, only one study specified the treatment of hypoactive subtype delirium. The design of this study was a post-hoc analysis of a double-blind, randomized, placebo-controlled study that used quetiapine as an adjuvant therapy to haloperidol. This study suggested that quetiapine appears to have more rapid resolution of many delirium symptoms, including a hypoactive state. These results were not statistically significant. The other 17 studies do not address the subtype.
Conclusion
There is poor evidence regarding the use of drugs for the management of hypoactive delirium. Not only the study design but the number of patients studied in the single trial is very limited, which affects the power of evidence. Double-blind, randomized, placebo controlled trials must be performed to guide the treatment and the management of hypoactive delirium.
References
Devlin , et al.: Impact of quetiapine on resolution of individual delirium symptoms in critically ill patients with delirium: a post-hoc analysis of a double-blind, randomized, placebo-controlled study. Crit Care 2011, 15: R215. 10.1186/cc10450
Acknowledgements
JPLMC and RA contributed equally to this work.
Author information
Authors and Affiliations
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Carvalho, J., Alvim, R., Martins, J. et al. Pharmacological treatment of hypoactive delirium in critically ill patients: a systematic review. Crit Care 17 (Suppl 3), P36 (2013). https://doi.org/10.1186/cc12652
Published:
DOI: https://doi.org/10.1186/cc12652